Are you a woman whoa��s not horny enough?
Then there may be good news for you. America has approved the first medicine to treat low sexual desire in women, Reuters reported.
The medicine does come with a strong warning though about low blood pressure and other side effects, especially when ita��s combined with alcohol.
The American Food and Drug Administration said the pink pill, to be sold under the brand name Addyi and made by privately held Sprout Pharmaceuticals, will only be available through certified and specially trained health care professionals and pharmacies due to its safety issues.
Addyi, whose chemical name is flibanserin, is designed for premenopausal women whose lack of sexual desire causes distress.
The condition is formally known as hypoactive sexual desire disorder, or HSDD. The drug needs to be taken daily.
Addyi has been nicknamed the a�?female Viagraa�? even though it does not work like the Pfizer Inca��s blockbuster Viagra pill for men that became the first approved drug for erectile dysfunction in 1998.
a�?This is the biggest breakthrough in womena��s sexual health since the advent of a�?the Pilla�� for contraception, The National Consumers League said in a statement.
a�?It validates (and) legitimises female sexuality as an important component of health.a�?
But Public Citizen, a consumer watchdog group that testified against the drug earlier this year, predicted that Addyi will be pulled from the market within a few years because of a�?serious dangers to women, with little benefita�? to them. a�?Unfortunately, we havena��t heard the last of this drug.a�?
Unlike Viagra, which affects blood flow to the genitals, Addyi is meant to activate sexual impulses in the brain. It is similar to a class of other drugs known as selective serotonin reuptake inhibitors, or SSRIa��s, that include antidepressants such as Prozac.
Women who took Addyi in a clinical study had an increase of about one sexually satisfying event per month compared with those taking a placebo. Advocates claim that increase is meaningful. Critics say the small benefit is outweighed by the druga��s risks. a�� Reuters